

JPET #101832

# Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction

Yeji Song, John C. Shryock, Stefan Wagner, \*Lars S. Maier, and \*Luiz Belardinelli

Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida (Y.S.);  
Pharmacological Sciences, CV Therapeutics, Inc., Palo Alto, California (J.C.S., L.B.); and  
Department of Cardiology and Pneumology, Georg-August-University Göttingen, Göttingen,  
Germany (S.W., L.S.M.)

JPET #101832

Running title: Attenuation of arrhythmogenic actions of ROS

Corresponding author:

Yeja Song

Division of Cardiovascular Medicine

University of Florida

1600 SW Archer Road, M-411

Gainesville, FL 32610-0277

USA

Tel: (352)392-3078

Fax: (352)392-5885

E-mail: [songy@medicine.ufl.edu](mailto:songy@medicine.ufl.edu)

Number of text pages:	23
Number of tables:	0
Number of figures:	8
Number of references:	37
Number of words in abstract:	246
Number of words in introduction:	530
Number of words in Discussion:	1214

JPET #101832

Nonstandard abbreviations:

APD, action potential duration;

EAD, early afterdepolarization;

$I_{Ca(L)}$ , L-type  $Ca^{2+}$  current;

$I_{Na-Ca}$ ,  $Na^+$ - $Ca^{2+}$  exchange current;

Late  $I_{Na}$ , late sodium current;

NCX, sodium-calcium exchange(r);

ROS, reactive oxygen species;

TTX, tetrodotoxin

Recommended section assignment: Cardiovascular

## Abstract

Reactive oxygen species (ROS), including hydrogen peroxide ( $\text{H}_2\text{O}_2$ ), cause intracellular calcium overload and ischemia-reperfusion damage. The objective of this study was to examine the hypothesis that  $\text{H}_2\text{O}_2$ -induced arrhythmic activity and contractile dysfunction are the result of an effect of  $\text{H}_2\text{O}_2$  to increase the magnitude of the late sodium current (late  $I_{\text{Na}}$ ). Guinea pig and rabbit isolated ventricular myocytes were exposed to  $\text{H}_2\text{O}_2$  (200  $\mu\text{mol/L}$ ). Transmembrane voltages and currents, and twitch shortening were measured using the whole-cell patch-clamp technique and video edge detection, respectively. Intracellular concentrations of sodium ( $[\text{Na}^+]_i$ ) and calcium ( $[\text{Ca}^{2+}]_i$ ) were determined by fluorescence measurements.  $\text{H}_2\text{O}_2$  caused a persistent late  $I_{\text{Na}}$  that was almost completely inhibited by tetrodotoxin (TTX, 10  $\mu\text{mol/L}$ ).  $\text{H}_2\text{O}_2$  prolonged the action potential duration (APD), slowed the relaxation rate of cell contraction, and induced early afterdepolarizations (EADs) and aftercontractions.  $\text{H}_2\text{O}_2$  also caused increases of  $[\text{Na}^+]_i$  and  $[\text{Ca}^{2+}]_i$ . Ranolazine (10  $\mu\text{mol/L}$ ), a novel inhibitor of late  $I_{\text{Na}}$ , attenuated  $\text{H}_2\text{O}_2$ -induced late  $I_{\text{Na}}$  by  $51 \pm 9\%$ . TTX (2  $\mu\text{mol/L}$ ) or ranolazine (10  $\mu\text{mol/L}$ ) attenuated  $\text{H}_2\text{O}_2$ -induced APD prolongation and suppressed EADs. Ranolazine accelerated the twitch relaxation rate in the presence of  $\text{H}_2\text{O}_2$  and abolished  $\text{H}_2\text{O}_2$ -induced aftercontractions. Pretreatment of myocytes with ranolazine delayed and reduced the increases of APD,  $[\text{Na}^+]_i$  and  $[\text{Ca}^{2+}]_i$  caused by  $\text{H}_2\text{O}_2$ . In conclusion, the results confirm the hypothesis that an increase in late  $I_{\text{Na}}$  during exposure of ventricular myocytes to  $\text{H}_2\text{O}_2$  contributes to electrical and contractile dysfunction, and suggest that inhibition of late  $I_{\text{Na}}$  may offer protection against ROS-induced  $\text{Na}^+$  and  $\text{Ca}^{2+}$  overload.

## Introduction

Although the exact role of hydrogen peroxide ( $H_2O_2$ ) and other reactive oxygen species (ROS) in pathological processes is still under investigation, increasing evidence strongly suggests a link between ROS and ischemia-reperfusion injury (Dhalla et al, 2000; Turoczi et al, 2003; Paradies et al, 2004), “stunned myocardium”, and the development and progression of heart failure (Bolli and Marbán, 1999; Zeitz et al, 2002; Sawyer et al, 2002; Liu et al, 2005). The myocardial tissue concentration of  $H_2O_2$  is significantly elevated in hearts exposed to ischemia-reperfusion (Slezak et al, 1995) and in the failing heart (Ide et al, 2000). ROS appear to play a major role in the dysregulation of intracellular concentrations of sodium ( $[Na^+]_i$ ) and calcium ( $[Ca^{2+}]_i$ ) in ischemia/reperfusion injury (Bolli and Marbán, 1999; Zeitz et al, 2002). This effect of ROS is accompanied by cellular electrical instability (e.g., arrhythmias) and contractile dysfunction characterized by a marked increase in diastolic tension (Zeitz et al, 2002; Hara et al, 1993). The cellular  $Ca^{2+}$  overload caused by ROS has been proposed to be due to a rise in  $[Na^+]_i$  followed by  $Ca^{2+}$  influx via the reverse mode of the  $Na^+ - Ca^{2+}$  exchanger (NCX) (Wagner et al, 2003). As to the mechanism of the ROS-induced rise in  $[Na^+]_i$ , there is evidence in support of an increased entry of  $Na^+$  via non-inactivating  $Na^+$  channels (Ward and Giles, 1997), an enhanced  $Na^+ - H^+$  exchanger activity (Sabri et al, 1998), and an impaired  $Na^+ - K^+ - ATPase$  function (Kim and Akera, 1987). The amplitude of late  $Na^+$  current (via non-inactivating  $Na^+$  channels) and  $[Na^+]_i$  and  $[Ca^{2+}]_i$  are significantly increased in myocytes isolated from ischemic (Kihara et al, 1989; Haigney et al, 1994; Huang et al, 2001) or failing hearts (Pogwizd et al, 2003; Valdivia et al, 2005). It has been shown that the increase in  $[Ca^{2+}]_i$  caused by ROS is attenuated by an NCX inhibitor (Zeitz et al, 2002) and is exacerbated in cells overexpressing NCX (Wagner et al, 2003). Furthermore, hypoxia-induced  $Na^+$  and  $Ca^{2+}$  loading of cardiac myocytes can be reduced

JPET #101832

by blockade of  $I_{Na}$  (Haigney et al, 1994). A rise of  $[Ca^{2+}]_i$  caused by hypoxia can also be prevented by inhibition of the  $Na^+$ - $Ca^{2+}$  exchanger (Ziegelstein et al, 1992). Interestingly, verapamil does not attenuate the increase in  $[Ca^{2+}]_i$  caused by ROS, indicating that the increase in  $Ca^{2+}$  entry into myocardial cells is not through L-type  $Ca^{2+}$  channels (Zeitz et al, 2002). Thus, the  $Ca^{2+}$  overload caused by ROS is likely due to a rise in  $[Na^+]_i$  that in turn leads to an increased exchange of intracellular  $Na^+$  for extracellular  $Ca^{2+}$  via NCX.

The objective of the present study was to determine the contribution of the late  $Na^+$  current (late  $I_{Na}$ ) to the rises in  $[Na^+]_i$  and  $[Ca^{2+}]_i$ , and to the accompanying electrical and contractile dysfunctions caused by  $H_2O_2$ . To determine the role of late  $I_{Na}$ , we used low concentrations ( $<10 \mu M$ ) of the putative  $Na^+$  channel blocker tetrodotoxin (TTX), and of ranolazine, a cardioprotective agent that preferentially inhibits late relative to peak  $I_{Na}$  (Undrovinas et al, 2006). Ranolazine has previously been shown to markedly attenuate, in a concentration-dependent manner, the increase in left ventricular diastolic pressure caused by  $H_2O_2$  in rat isolated, perfused hearts (Matsumura et al, 1998).

## Methods

### Chemicals

H<sub>2</sub>O<sub>2</sub> was purchased from Fisher (Fair Lawn, NJ) and Merck (Darmstadt, Germany). TTX was purchased from Sigma (St. Louis, MO). Ranolazine [(±)-N-(2,6-dimethylphenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine)], a piperazine derivative (Matsumura et al, 1998), was synthesized by CV Therapeutics (Palo Alto, CA).

### Isolation of Ventricular Myocytes

Electrophysiological studies were performed on guinea pig ventricular myocytes at the University of Florida; intracellular Na<sup>+</sup> and Ca<sup>2+</sup> measurements were conducted on rabbit ventricular myocytes at Georg-August-University Göttingen. Use of animals was in accordance with the Guide for the *Care and Use of Laboratory Animals* published by US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the Institutional Animal Care and Use Committee of the University of Florida. Ventricular myocytes were isolated from adult, female Hartley guinea pigs and Chinchilla bastard rabbits, with standard enzymatic procedures described previously (Wagner et al, 2003; Song et al, 2004).

### Measurements of Transmembrane Potential and Current

Guinea pig ventricular myocytes were placed into a recording chamber that was bathed with pre-warmed (35-36 °C) Tyrode solution, without or with drug(s), at a rate of 2 ml/min. The Tyrode solution contained (in mmol/L) 135 NaCl, 4.6 KCl, 1.8 CaCl<sub>2</sub>, 1.1 MgSO<sub>4</sub>, 10 glucose and 10 HEPES, pH 7.4. The temperature of the bathing media in a given experiment did not vary more than 0.3 °C. Transmembrane voltages and currents were recorded from quiescent, rod-shaped myocytes with clear striations, using borosilicate glass pipettes (1-3 MΩ resistance when filled) in a whole-cell configuration of the patch clamp technique. An Axopatch-200 amplifier, a

JPET #101832

DigiData interface and a computer with pCLAMP software (Axon Instruments, Union City, CA) were used to amplify, store, and analyze the recorded signals. The electrode capacitance and whole-cell capacitance currents were maximally compensated with the amplifier. The series resistance was compensated by 60-80%. The liquid junction potential between pipette and bath medium was calculated with pCLAMP software and corrected online.

When measuring action potentials, recording pipettes were filled with a solution containing (in mmol/L) 120 K-aspartate, 20 KCl, 1 MgSO<sub>4</sub>, 4 Na<sub>2</sub>ATP, 0.1 Na<sub>3</sub>GTP, and 10 HEPES, pH 7.2. For inducing action potentials, a 5-ms depolarizing pulse was applied at a frequency of 0.16 Hz. The duration of the action potential was measured from onset of upstroke to 50% of repolarization (APD<sub>50</sub>).

To elicit late I<sub>Na</sub>, myocytes were voltage-clamped at a holding potential of -90 mV, and a 300-ms depolarizing pulse to -30 mV was applied at a frequency of 0.16 Hz. In experiments to determine the effect of ranolazine on late I<sub>Na</sub>, K<sup>+</sup> and Ca<sup>2+</sup> were omitted from the bath and pipette solutions to reduce contamination of I<sub>Na</sub> by K<sup>+</sup> and Ca<sup>2+</sup> currents. In these experiments, recording pipettes were filled with (in mmol/L) 120 Cs-aspartate, 20 CsCl, 1 MgSO<sub>4</sub>, 4 Na<sub>2</sub>ATP, 0.1 Na<sub>3</sub>GTP, and 10 HEPES, pH 7.2. The magnitude of late I<sub>Na</sub> was determined by integration of the current over the last 50 ms of the -30 mV clamp pulse, using the integration (area) feature of the pCLAMP program.

### **Measurement of Cell Contraction**

Twitch shortenings of guinea pig ventricular myocytes were elicited by field stimulation from a Grass-S88 stimulator (Quincy, MA). The amplitude of twitch shortening was determined by a video-motion detector (Crescent Electronics, Logan, UT), and was recorded on a chart recorder (Gould 2200S, Cleveland, OH). In this study, a twitch shortening denotes a normal



JPET #101832

systolic contraction, whereas an early aftercontraction denotes an additional contraction that occurs during relaxation and is triggered by events following the preceding normal contraction. The amplitude of twitch shortening was measured from maximal cell relaxation to peak contraction, and the rate of relaxation was calculated by dividing the amplitude ( $\mu\text{m}$ ) with the time (s) required from peak contraction to maximal relaxation.

### **Measurement of Intracellular Sodium and Calcium**

Rabbit ventricular myocytes on laminin-coated recording chambers were loaded with either 10  $\mu\text{mol/L}$  SBFI-AM for 2 h or 10  $\mu\text{mol/L}$  Indo1-AM for 30 min, in the presence of 0.02% (w/v) pluronic acid (Molecular Probes, Eugene, OR). The chambers were mounted on the stage of an inverted microscope (Nikon Eclipse TE2000-U) and superfused with normal Tyrode solution (37°C) containing (in mmol/L) 140 NaCl, 4 KCl, 1 MgCl<sub>2</sub>, 5 HEPES, 10 glucose, 2 CaCl<sub>2</sub>, pH 7.4. Myocytes were continuously paced at 0.5 Hz using electrical field stimulation (10-20 V). Intracellular SBFI was alternatively excited at 340 and 380 nm and emitted epifluorescence was monitored at 510 nm for both wavelengths ( $F_{340}$  and  $F_{380}$ ). Intracellular Indo1 was excited at 360 nm and emitted epifluorescence was measured at 405 and 485 nm. For both dyes, fluorescence emission was recorded using IonWizard software (IonOptix Corporation, Boston, MA). After washing out the external dye for 10 min, background fluorescence was determined for each excitation or emission wavelength. The ratios of  $F_{340}/F_{380}$  and  $F_{405}/F_{485}$ , respectively, were then calculated from the background-subtracted emission intensities at each wavelength and converted to  $[\text{Na}^+]_i$  and  $[\text{Ca}^{2+}]_i$  with calibration curves. In situ calibration of SBFI was accomplished by exposing myocytes to bath solutions containing 0, 5, 10 and 20 mmol/L Na<sup>+</sup> in the presence of 10  $\mu\text{mol/L}$  gramicidin D, 80  $\mu\text{mol/L}$  monensin and 50  $\mu\text{mol/L}$  strophanthidin (Maier et al, 1997). The solutions with various concentrations of Na<sup>+</sup> were

JPET #101832

prepared from two stock solutions of equal ionic strength containing (in mmol/L) 140 NaCl, 10 HEPES and 1 EGTA or (in mmol/L) 140 KCl, 10 HEPES and 1 EGTA, pH was adjusted to 7.2 with Tris base. In situ calibration of Indo1 was accomplished using the equation  $[Ca^{2+}]_i = K_D \cdot \beta [(R - R_{min}) / (R_{max} - R)]$  as previously described (Bassani et al, 1995).

### **Statistical Analysis**

Data are expressed as mean  $\pm$  SEM. Values of “n” indicate the number of cells studied. The Student’s t-test, one-way repeated measures ANOVA followed by Student-Newman-Keuls test, and two-way ANOVA were applied where it was appropriate. A difference with a *p* value < 0.05 was considered statistically significant.

## Results

### **Ranolazine and TTX inhibited H<sub>2</sub>O<sub>2</sub>-induced late sodium current of guinea pig ventricular myocytes.**

Late I<sub>Na</sub> in the absence of drug was a small inward current (Figure 1, A and B). Incubation of cells in 200 μmol/L H<sub>2</sub>O<sub>2</sub> caused an increase of late I<sub>Na</sub> from -3.419±0.392 to -6.215±0.471 nC (Figure 1A). Ranolazine (10 μmol/L), an inhibitor of late I<sub>Na</sub>, reduced the current to -5.072±0.440 nC in the continued presence of H<sub>2</sub>O<sub>2</sub> (n = 10, *p* < 0.01; Figure 1A), a 51±9% decrease of H<sub>2</sub>O<sub>2</sub>-induced late I<sub>Na</sub>. To confirm that the H<sub>2</sub>O<sub>2</sub>-induced late current was indeed a Na<sup>+</sup> current, the specific Na<sup>+</sup> channel blocker TTX (10 μmol/L) was applied in the presence of H<sub>2</sub>O<sub>2</sub>. Late I<sub>Na</sub> was increased by 200 μmol/L H<sub>2</sub>O<sub>2</sub> from -0.114±0.538 to -4.423±1.384 nC, and was decreased by TTX to -0.476±0.850 nC (n = 5, *p* < 0.01; Figure 1B), a decrease of 91±5%.

### **Ranolazine and TTX attenuated H<sub>2</sub>O<sub>2</sub>-induced action potential prolongation and early afterdepolarizations in guinea pig ventricular myocytes.**

An increase of late I<sub>Na</sub> caused by H<sub>2</sub>O<sub>2</sub> would cause prolongation of action potential duration (APD) and early afterdepolarizations (EADs), which may explain, at least in part, the arrhythmogenic effect of H<sub>2</sub>O<sub>2</sub> on cardiac myocytes. On the other hand, attenuation of late I<sub>Na</sub> may antagonize these effects of H<sub>2</sub>O<sub>2</sub>. Therefore, the interactions between H<sub>2</sub>O<sub>2</sub> and both ranolazine and TTX on action potentials were examined. For these experiments, equally effective concentrations of TTX (2 μmol/L) and ranolazine (10 μmol/L) were used. At these concentrations neither drug alone had a significant effect on APD (not shown). The earliest response to H<sub>2</sub>O<sub>2</sub> (200 μmol/L) was a progressive prolongation of APD. Prolonged treatment with H<sub>2</sub>O<sub>2</sub> led to development of EADs, followed by spontaneous activity and membrane

JPET #101832

depolarization (not shown). Both ranolazine (10  $\mu\text{mol/L}$ , Figure 2A) and TTX (2  $\mu\text{mol/L}$ , Figure 2B) attenuated an  $\text{H}_2\text{O}_2$ -induced prolongation of APD. The APD at 50% of repolarization ( $\text{APD}_{50}$ ) was increased by  $\text{H}_2\text{O}_2$  from  $204 \pm 15$  to  $280 \pm 18$  ms; ranolazine decreased the  $\text{APD}_{50}$  to  $235 \pm 13$  ms and attenuated by  $58 \pm 8\%$  the prolongation of APD caused by  $\text{H}_2\text{O}_2$  ( $n = 8$ ,  $p < 0.001$ ; Figure 2C). In another set of experiments,  $\text{H}_2\text{O}_2$  increased  $\text{APD}_{50}$  from  $177 \pm 4$  to  $232 \pm 9$  ms, and TTX decreased  $\text{APD}_{50}$  to  $198 \pm 6$  ms in the continued presence of  $\text{H}_2\text{O}_2$  ( $n = 5$ ,  $p < 0.001$ ; Figure 2D). When EADs were induced by  $\text{H}_2\text{O}_2$ , addition of either ranolazine (10  $\mu\text{mol/L}$ ,  $n = 3$ ) or TTX (2  $\mu\text{mol/L}$ ,  $n = 4$ ) resulted in suppression of the EADs (Figures 3 and 4, respectively).

Pretreatment of myocytes with ranolazine significantly blunted an increase of APD caused by  $\text{H}_2\text{O}_2$  and prevented induction by  $\text{H}_2\text{O}_2$  of EADs. In these experiments, myocytes were treated with either saline (control) or ranolazine (10  $\mu\text{mol/L}$ ) 3 min prior to application of  $\text{H}_2\text{O}_2$  and throughout the exposure to  $\text{H}_2\text{O}_2$  (200  $\mu\text{mol/L}$ ). Exposure of myocytes to  $\text{H}_2\text{O}_2$  led to an increase of  $\text{APD}_{50}$  (Figure 5). APD prolongation usually became apparent after 5 min of exposure to  $\text{H}_2\text{O}_2$  and increased progressively thereafter (Figure 5). After a 10-min exposure to  $\text{H}_2\text{O}_2$ ,  $\text{APD}_{50}$  was increased by  $61 \pm 7\%$  and EADs were induced in 7 out of 10 cells (action potentials with EADs were not included in  $\text{APD}_{50}$  calculation). In contrast,  $\text{APD}_{50}$  was increased by only  $11 \pm 6\%$  ( $p < 0.01$ ; Figure 5) in ranolazine-treated myocytes, and EADs were not observed in any of the 8 myocytes studied.

### **Ranolazine reversed $\text{H}_2\text{O}_2$ -induced contractile dysfunction of guinea pig ventricular myocytes.**

$\text{H}_2\text{O}_2$  (200  $\mu\text{mol/L}$ ) initially increased the amplitude of myocyte contractile shortening and induced aftercontractions that delayed contractile relaxation (Figure 6A, record b).

Prolonged treatment of myocytes with  $\text{H}_2\text{O}_2$  eventually caused spontaneous contractions and

JPET #101832

decreases of contractile amplitude and rate and extent of relaxation (Figure 6A, record d).

Ranolazine (10  $\mu\text{mol/L}$ ) did not significantly change contractile amplitude in the presence of  $\text{H}_2\text{O}_2$  (Figure 6B), but suppressed aftercontractions (Figure 6A, record c).  $\text{H}_2\text{O}_2$  increased myocyte contractile amplitude from  $4.7 \pm 0.8$  to  $6.3 \pm 1.1$   $\mu\text{m}$  and decreased the rate of contractile relaxation from  $12.2 \pm 1.0$  to  $7.3 \pm 1.3$   $\mu\text{m/s}$  (Figure 6B). Ranolazine accelerated the relaxation rate from  $7.3 \pm 1.3$  to  $15.0 \pm 1.9$   $\mu\text{m/s}$  ( $n = 5$ ,  $p < 0.05$ ) in the presence of  $\text{H}_2\text{O}_2$  (Figure 6B).

### **Ranolazine attenuated $\text{H}_2\text{O}_2$ -induced intracellular $\text{Na}^+$ and $\text{Ca}^{2+}$ overload of rabbit ventricular myocytes.**

In this series of experiments, the effects of  $\text{H}_2\text{O}_2$  (200  $\mu\text{mol/L}$ ) on  $[\text{Na}^+]_i$ ,  $[\text{Ca}^{2+}]_i$  and contractions of rabbit ventricular myocytes were determined in the absence or presence of ranolazine (10  $\mu\text{mol/L}$ ).  $\text{H}_2\text{O}_2$  caused time-dependent increases of  $[\text{Na}^+]_i$  and  $[\text{Ca}^{2+}]_i$  (Figure 7) that led to a state of hypercontracture within  $14.8 \pm 1.0$  min (not shown). In the presence of ranolazine, time to  $\text{H}_2\text{O}_2$ -induced hypercontracture was significantly increased to  $19.3 \pm 1.1$  min ( $n = 14$ ,  $p < 0.05$ ). Consistent with this finding, ranolazine blunted the time-dependent increases of  $[\text{Na}^+]_i$  and  $[\text{Ca}^{2+}]_i$  during exposure to  $\text{H}_2\text{O}_2$ . There was a trend of reduction by ranolazine of baseline  $[\text{Na}^+]_i$ , from  $5.0 \pm 0.8$  to  $2.4 \pm 1.0$   $\text{mmol/L}$ , and baseline diastolic  $[\text{Ca}^{2+}]_i$ , from  $179 \pm 44$  to  $99 \pm 26$   $\text{nmol/L}$ , respectively. However, these changes were not statistically significant. After a 12-min incubation of myocytes with  $\text{H}_2\text{O}_2$ ,  $[\text{Na}^+]_i$  was increased to  $16.7 \pm 2.8$   $\text{mmol/L}$ , whereas in the presence of ranolazine,  $[\text{Na}^+]_i$  was significantly reduced to  $8.0 \pm 2.2$   $\text{mmol/L}$  ( $p < 0.05$ ; Figure 7, A and B). Similarly,  $\text{H}_2\text{O}_2$ -induced increase of  $[\text{Ca}^{2+}]_i$  was significantly attenuated by ranolazine. At the end of a 12-min incubation with  $\text{H}_2\text{O}_2$ , diastolic  $[\text{Ca}^{2+}]_i$  was  $569 \pm 106$  and  $338 \pm 61$   $\text{nmol/L}$ , respectively, in the absence and presence of ranolazine ( $p < 0.05$ ; Fig 7, C and D).

## Discussion

The major finding of this study is that blocking late  $I_{Na}$  with either ranolazine or TTX attenuates  $H_2O_2$ -induced arrhythmic activity and contractile dysfunction in cardiac myocytes. In addition, ranolazine was found to significantly reduce the rise in  $[Na^+]_i$  and  $[Ca^{2+}]_i$  caused by  $H_2O_2$ . The results of the study suggest that inhibition of late  $I_{Na}$  may attenuate reactive oxygen species-induced cardiac dysfunction.

The hypothesis tested in the present study can be summarized as follows (Figure 8): ROS, such as  $H_2O_2$ , increase late  $I_{Na}$  and thereby cause 1) prolongation of APD and induction of EADs, and 2) a rise in  $[Na^+]_i$  which, because intracellular  $Na^+$  is exchanged for extracellular  $Ca^{2+}$  via NCX, causes cellular  $Ca^{2+}$  overload.  $Ca^{2+}$  overload of cardiomyocytes is associated with electrical instability (i.e., arrhythmias) and contractile dysfunction (i.e., impaired relaxation). Hence, by reducing the increase in late  $I_{Na}$ , the deleterious effects of  $H_2O_2$  on cardiomyocyte function (electrical and contractile) can be attenuated. In support of the hypothesis (Figure 8), results of other studies have shown that  $H_2O_2$  can cause increases of late  $I_{Na}$  (Ward and Giles, 1997; Ma et al, 2005), intracellular  $Na^+$  and  $Ca^{2+}$  (Wagner et al, 2003), and ventricular diastolic tension and pressure (Zeitz et al, 2002; Hara et al, 1993).

To verify the hypothesis just described (Figure 8), we measured late  $I_{Na}$ , action potentials, cell contractions, and intracellular concentrations of  $Na^+$  and  $Ca^{2+}$ . We found that ranolazine and TTX effectively reduced  $H_2O_2$ -induced late  $I_{Na}$  (Figure 1), action potential prolongation (Figure 2), EADs (Figures 3-4), and cell contractile dysfunction (Figure 6). Pretreatment of myocytes with ranolazine significantly delayed or prevented action potential prolongation (Figure 5), cell contracture, and increases of  $[Na^+]_i$  and  $[Ca^{2+}]_i$  caused by subsequent exposure of cells to  $H_2O_2$  (Figure 7). Thus, the hypothesis presented in Figure 8 is fully supported by the present results. In

JPET #101832

addition, ranolazine has been reported to reduce H<sub>2</sub>O<sub>2</sub>-induced contractile dysfunction of rat isolated hearts (Matsumura et al, 1998). The results of the present study using ventricular myocytes thus provide an ionic mechanism (i.e., inhibition of late I<sub>Na</sub>) to explain the protective action of ranolazine against ROS-induced increases of left ventricular end-diastolic and coronary perfusion pressures (Matsumura et al, 1998).

Although the amplitude of late I<sub>Na</sub> recorded in the absence of drugs is small, late I<sub>Na</sub> is found to contribute to the regulation of APD (Kiyosue and Arita, 1989; Maltsev et al, 1998; Sakmann et al, 2000). Blocking late I<sub>Na</sub> with TTX caused a 10-20% decrease of APD (Kiyosue and Arita, 1989; Maltsev et al, 1998; Sakmann et al, 2000) and suppressed EADs of myocytes isolated from failing hearts (Maltsev et al, 1998). We found that in the absence of TTX or ranolazine, the amplitude of late I<sub>Na</sub> can be markedly enhanced by H<sub>2</sub>O<sub>2</sub> by several fold (data not shown). Therefore, an increase by H<sub>2</sub>O<sub>2</sub> of late I<sub>Na</sub> is expected to cause a significant prolongation of APD. Consistent with previous reports (Berezewicz and Horackova, 1991), we found that the early effect of H<sub>2</sub>O<sub>2</sub> on myocyte membrane potential was an increase in the duration of action potentials. This effect of H<sub>2</sub>O<sub>2</sub> can be largely explained by an increase of late I<sub>Na</sub>, because it was significantly attenuated by either ranolazine or TTX. Thus, blocking late I<sub>Na</sub> may be the key to reduce H<sub>2</sub>O<sub>2</sub>-induced arrhythmic activity and contractile dysfunction.

In myocytes pretreated with ranolazine both [Na<sup>+</sup>]<sub>i</sub> and [Ca<sup>2+</sup>]<sub>i</sub> were found to be lower, prior to the addition of H<sub>2</sub>O<sub>2</sub>, than in untreated myocytes. Whether this observation is due to an inherent variation in the intracellular ion concentrations or to a true effect of ranolazine remains to be investigated. However, in another study of rat isolated perfused hearts in which this issue was investigated, ranolazine at a concentration of 10 μmol/L did not lower baseline systolic or diastolic [Ca<sup>2+</sup>]<sub>i</sub> (Fraser et al, 2005). Regardless, a possible explanation for the lower [Na<sup>+</sup>]<sub>i</sub> and

JPET #101832

$[Ca^{2+}]_i$  in myocytes pretreated with ranolazine is that this piperazine derivative by reducing basal  $I_{Na}$ , albeit small in normal myocytes, could indeed reduce basal  $[Na^+]_i$  and  $[Ca^{2+}]_i$ .

Evidence in support of this explanation is that ranolazine, like TTX, can cause small shortening of the APD. The net effect of ranolazine on ventricular APD depends on the relative contribution of delayed rectifier  $K^+$  current and late  $I_{Na}$  to the repolarization (Song et al, 2004).

There are potential limitations to this study. Firstly,  $H_2O_2$  might elevate  $[Na^+]_i$  via enhancing  $Na^+-H^+$  exchange (Sabri et al, 1998) or reducing  $Na^+-K^+-ATPase$  (Kim and Akera, 1987) activity. Inhibition of  $Na^+-K^+-ATPase$  may cause a transient prolongation of action potential (Levi, 1991). However, it is unlikely that modulation of  $Na^+-K^+-ATPase$  plays a significant role in  $H_2O_2$ -induced action potential prolongation and EADs, because the effect of  $H_2O_2$  was blocked by TTX. Furthermore, ranolazine at 20  $\mu\text{mol/L}$  had no effect on the  $Na^+-H^+$  exchanger in MDCK cells (CV Therapeutics, 2003).

Secondly, our data interpretation is dependent on the selectivity of TTX and ranolazine for  $Na^+$  channels. The late (persistent)  $I_{Na}$  is more susceptible than the peak inward  $I_{Na}$  to the inhibitory effect of TTX (Kiyosue and Arita, 1989; Maltsev et al, 1998). In the present study, TTX at a low concentration of 2  $\mu\text{mol/L}$  significantly attenuated  $H_2O_2$ -induced action potential prolongation and EADs, whereas it had little effect on the basal action potentials (in the absence of  $H_2O_2$ , data not shown). This result indicates that the prolongation of APD caused by  $H_2O_2$  can be mainly attributed to an increase of late  $I_{Na}$ . Consistent with the findings of the present study, TTX has been shown to markedly attenuate the deleterious effects ( $Ca^{2+}$ -overload, diastolic dysfunction, etc.) caused by ROS and palmitoyl-L-carnitine, known to increase late  $I_{Na}$  (Ver Donck and Borgers, 1991; Hara et al, 1997). Ranolazine has also been reported to be a rather selective (38-fold) inhibitor of late relative to peak  $I_{Na}$  (Undrovinas et al, 2006). In ventricular



JPET #101832

myocytes of dogs with chronic heart failure, ranolazine inhibited peak and late  $I_{Na}$  with potencies of 244 and 6.5  $\mu\text{mol/L}$ , respectively (Undrovinas et al, 2006). Ranolazine at a concentration of 10  $\mu\text{mol/L}$  has been shown to effectively attenuate anemone toxin II-induced late  $I_{Na}$ , prolongation of APD, and formation of EADs (Song et al, 2004). Alternative explanations for the effect of ranolazine to attenuate  $\text{H}_2\text{O}_2$ -induced action potential prolongation and EADs are an inhibition of the L-type  $\text{Ca}^{2+}$  current ( $I_{Ca(L)}$ ) and/or  $\text{Na}^+$ - $\text{Ca}^{2+}$  exchange current ( $I_{Na-Ca}$ ). However, the  $\text{IC}_{50}$  values for ranolazine to inhibit  $I_{Ca(L)}$  and  $I_{Na-Ca}$  were reported to be around 300  $\mu\text{mol/L}$  and 91  $\mu\text{mol/L}$ , respectively (Antzelevitch et al, 2004; Schram et al, 2004). Moreover, we found that  $\text{H}_2\text{O}_2$  caused a decrease of  $I_{Ca(L)}$  in guinea pig ventricular myocytes (data not shown). Therefore, it is unlikely that putative inhibition by ranolazine of  $I_{Ca(L)}$ ,  $I_{Na-Ca}$  and/or peak  $I_{Na}$  can explain its attenuation of the effect of  $\text{H}_2\text{O}_2$ . It is also unlikely that ranolazine reduces the effects of  $\text{H}_2\text{O}_2$  via radical scavenging or antioxidant actions, because ranolazine does not decrease  $\text{H}_2\text{O}_2$ -induced lipid peroxidation (Matsumura et al, 1998).

In summary, block of late  $I_{Na}$  by TTX or ranolazine attenuates the deleterious effects of  $\text{H}_2\text{O}_2$  on electrical and contractile functions and cellular  $\text{Na}^+$  and  $\text{Ca}^{2+}$  homeostasis of cardiac myocytes. The results of the present study suggest that an increase of late  $I_{Na}$  is a major ionic mechanism underlying the cardiac actions of  $\text{H}_2\text{O}_2$ . Reducing late  $I_{Na}$  may be a critical step to attenuate ROS-induced myocardial dysfunction.

## References

- Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, and Thomas G (2004) Electrophysiological effects of ranolazine, a novel antianginal agent with Antiarrhythmic properties. *Circulation* **110**:904-910.
- Bassani JWM, Bassani RA, and Bers DM (1995) Calibration of Indo-1 and resting intracellular  $[Ca]_i$  in intact rabbit cardiac myocytes. *Biophys J* **68**:1453-1460.
- Berezewicz A and Horackova M (1991) Alterations in electrical and contractile behavior of isolated cardiomyocytes by hydrogen peroxide: possible ionic mechanism. *J Mol Cell Cardiol* **23**:899-918.
- Bolli B and Marbán E (1999) Molecular and cellular mechanisms of myocardial stunning. *Physiol Rev* **79**:609-634.
- CV Therapeutics (2003) Ranexa (renolazine) FDA review documents. NDA 21-526.
- Dhalla NS, Elmoselhi AB, Hata T, and Makino N (2000) Status of myocardial antioxidants in ischemia-reperfusion injury. *Cardiovasc Res* **47**:446-456.
- Fraser H, Belardinelli L, Wang L, McVeigh JJ, and Clanahan AS (2005) Inhibition of late  $I_{Na}$  by ranolazine reduces  $Ca^{2+}$  overload and LV mechanical dysfunction in ejecting rat hearts. *Eur Heart J* **26**(Abstract Supplement):414.
- Haigney MCP, Lakatta EG, Stern MD, and Silverman HS (1994) Sodium channel blockade reduces hypoxic sodium loading and sodium-dependent calcium loading. *Circulation* **90**:391-399.
- Hara A, Arakawa J, Hashizume H, and Abiko Y (1997) Beneficial effects of dilazep on the palmitoyl-L-carnitine-induced derangements in isolated, perfused rat heart: comparison with tetrodotoxin. *Jpn J Pharmacol* **74**:147-153.

JPET #101832

- Hara A, Matsumura H, and Abiko Y (1993) Lidocaine attenuates both mechanical and metabolic changes induced by hydrogen peroxide in the rat heart. *Am J Physiol* **265**:H1478-H1485.
- Huang B, El-Sherif T, Gidh-Jain M, Qin D, and El-Sherif N (2001) Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium. *J Cardiovasc Electrophysiol* **12**:218-225.
- Ide T, Tsutsui H, Kinugawa S, Suematsu N, Hayashidani S, Ichikawa K, Utsumi H, Machida Y, Egashira K, and Takeshita A (2000) Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. *Circ Res* **86**:152-157.
- Kihara Y, Grossman W, and Morgan JP (1989) Direct measurement of changes in intracellular calcium transients during hypoxia, ischemia, and reperfusion of the intact mammalian heart. *Circ Res* **65**:1029-1044.
- Kim M-S and Akera T (1987) O<sub>2</sub> free radicals: cause of ischemia-reperfusion injury to cardiac Na<sup>+</sup>-K<sup>+</sup>-ATPase. *Am J Physiol* **252**:H252-H257.
- Kiyosue T and Arita M (1989) Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes. *Circ Res* **64**:389-397.
- Levi AJ (1991) The effect of strophanthidin on action potential, calcium current and contraction in isolated guinea-pig ventricular myocytes. *J Physiol* **443**:1-23.
- Liu H, Colavitti R, Rovira II, and Finkel T (2005) Redox-dependent transcriptional regulation. *Circ Res* **97**:967-974.
- Ma J-H, Luo A-T, and Zhang P-H (2005) Effect of hydrogen peroxide on persistent sodium current in guinea pig ventricular myocytes. *Acta Pharmacologica Sinica* **26**:828-834.
- Maier LS, Pieske B, and Allen DG (1997) Influence of stimulation frequency on [Na<sup>+</sup>]<sub>i</sub> and contractile function in Langendorff-perfused rat heart. *Am J Physiol* **273**:H1246-H1254.

JPET #101832

Maltsev VA, Sabbah HN, Higgins RSD, Silverman N, Lesch M, and Undrovinas AI (1998)

Novel, ultraslow inactivation sodium current in human ventricular cardiomyocytes.

*Circulation* **98**:2545-2552.

Matsumura H, Hara A, Hashizume H, Mazuyasu K, and Abiko Y (1998) Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. *Jpn J Pharmacol* **77**:31-39.

Paradies G, Petrosillo G, Pistolese M, Venosa ND, Federici A, and Ruggiero FM (2004)

Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart. *Circ Res* **94**:53-59.

Pogwizd SM, Sipido KR, Verdonck F, and Bers DM (2003) Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. *Cardiovasc Res* **57**:887-896.

Sabri A, Byron KL, Samarel AM, Bell J, and Lucchesi PA (1998) Hydrogen peroxide activates mitogen-activated protein kinases and Na<sup>+</sup>-H<sup>+</sup> exchange in neonatal rat cardiac myocytes. *Circ Res* **82**:1053-1062.

Sakmann BFAS, Spindler AJ, Bryant SM, Linz KW, and Noble D (2000) Distribution of a persistent sodium current across the ventricular wall in guinea pigs. *Circ Res* **87**:910-914.

Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, and Colucci WS (2002) Role of oxidative stress in myocardial hypertrophy and failure. *J Mol Cell Cardiol* **34**:379-388.

Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, and Nattel S (2004) Ranolazine: ion-channel-blocking actions and *in vivo* electrophysiological effects. *Br J Pharmacol* **142**:1300-1308.

JPET #101832

Slezak J, Tribulova N, Pristacova J, Uhrík B, Thomas T, Khaper N, Kaul N, and Singal PK

(1995) Hydrogen peroxide changes in ischemic and reperfused heart. *Am J Pathol* **147**:772-781.

Song Y, Shryock JC, Wu L, and Belardinelli L (2004) Antagonism by ranolazine of the pro-arrhythmic effects of increasing late  $I_{Na}$  in guinea pig ventricular myocytes. *J Cardiovasc Pharmacol* **44**:192-199.

Turoczi T, Jun L, Cordis G, Morris JE, Maulik N, Stevens RG, and Das DK (2003) HFE mutation and dietary iron content interact to increase ischemia/reperfusion injury of the heart in mice. *Circ Res* **92**:1240-1246.

Undrovinas AI, Belardinelli L, Undrovinas NA, and Sabbah HN (2006) Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. *J Cardiovasc Electrophysiol* (in press).

Valdivia CR, Chu WW, Pu J, Foell JD, Haworth RA, Wolff MR, Kamp TJ, and Makielski (2005) Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. *J Mol Cell Cardiol* **38**:475-483.

Ver Donck L and Borgers M (1991) Myocardial protection by R 56865: a new principle based on prevention of ion channel pathology. *Am J Physiol* **261**:H1828-1835.

Wagner S, Seidler T, Picht E, Maier LS, Kazanski V, Teucher N, Schillinger W, Pieske B, Isenberg G, Hasenfuss G, and Kögler H (2003)  $Na^+$ - $Ca^{2+}$  exchanger overexpression predisposes to reactive oxygen species-induced injury. *Cardiovasc Res* **60**:404-412.

Ward CA and Giles WR (1997) Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. *J Physiol* **500**:631-642.

JPET #101832

Zeit O, Maass AE, Nguyen PV, Hensmann G, Kögler H, Möller K, Hasenfuss G, and Janssen

PML (2002) Hydroxyl radical-induced acute diastolic dysfunction is due to calcium overload via reverse-mode  $\text{Na}^+$ - $\text{Ca}^{2+}$  exchange. *Circ Res* **90**:988-995.

Ziegelstein RC, Zweier JL, Mellits ED, Younes A, Lakatta EG, Stern MD, and Silverman HS

(1992) Dimethylthiourea, an oxygen radical scavenger, protects isolated cardiac myocytes from hypoxic injury by inhibition of  $\text{Na}^+$ - $\text{Ca}^{2+}$  exchange and not by its antioxidant effects. *Circ Res* **70**:804-811.

JPET #101832

## Footnotes

\* Authors contributed equally.

Yeja Song received a research grant from CV Therapeutics.

Lars S. Maier is funded by the Deutsche Forschungsgemeinschaft (DFG) through an Emmy Noether-grant (MA 1982/1-4), by a Young Investigator Award of the GlaxoSmithKline Research Foundation, and by a grant from the Medical Faculty of the University of Göttingen (Anschubfinanzierung).

Corresponding author (for reprints):

Yeja Song

Division of Cardiovascular Medicine

University of Florida

1600 SW Archer Road, M-411

Gainesville, FL 32610-0277

USA

E-mail: [songy@medicine.ufl.edu](mailto:songy@medicine.ufl.edu)

## Figure Legends

Figure 1. Ranolazine (10  $\mu\text{mol/L}$ , panel A) and tetrodotoxin (TTX, 10  $\mu\text{mol/L}$ , panel B) attenuated hydrogen peroxide ( $\text{H}_2\text{O}_2$ , 200  $\mu\text{mol/L}$ )-induced late sodium current of guinea pig ventricular myocytes. Sodium current was elicited by 300-ms voltage-clamp pulses from -90 to -30 mV. Myocytes were sequentially treated with a) no drug (control), b)  $\text{H}_2\text{O}_2$ , and c)  $\text{H}_2\text{O}_2$  plus either ranolazine or TTX.

Figure 2. Attenuation by ranolazine (Ran, 10  $\mu\text{mol/L}$ ) and tetrodotoxin (TTX, 2  $\mu\text{mol/L}$ ) of hydrogen peroxide ( $\text{H}_2\text{O}_2$ , 200  $\mu\text{mol/L}$ )-induced prolongation of action potential duration of guinea pig ventricular myocytes. Panels A and B: superimposed action potentials recorded from a single cell in the presence of a) no drug (control), b)  $\text{H}_2\text{O}_2$ , and c)  $\text{H}_2\text{O}_2$  plus Ran (panel A) or TTX (panel B). Panels C and D: summary of data from experiments similar to those shown in Panels A and B, respectively. \* and \*\*,  $p < 0.001$  vs. control and  $\text{H}_2\text{O}_2$  alone, respectively.

Figure 3. Inhibition by ranolazine (10  $\mu\text{mol/L}$ ) of hydrogen peroxide ( $\text{H}_2\text{O}_2$ , 200  $\mu\text{mol/L}$ )-induced early afterdepolarizations (EADs) of a guinea pig ventricular myocyte. The myocyte was sequentially treated with a) no drug (control), b)  $\text{H}_2\text{O}_2$ , c)  $\text{H}_2\text{O}_2$  plus ranolazine, and d)  $\text{H}_2\text{O}_2$  alone (to wash out ranolazine). Each panel shows five superimposed, consecutive action potentials. Arrows indicate EADs.

Figure 4. Inhibition by tetrodotoxin (TTX, 2  $\mu\text{mol/L}$ ) of hydrogen peroxide ( $\text{H}_2\text{O}_2$ , 200  $\mu\text{mol/L}$ )-induced early afterdepolarizations (EADs) of a guinea pig ventricular myocyte. The myocyte was treated with a) no drug (control), b)  $\text{H}_2\text{O}_2$ , c)  $\text{H}_2\text{O}_2$  plus TTX, and d)  $\text{H}_2\text{O}_2$  alone (to wash



JPET #101832

out TTX). Each panel shows three superimposed, consecutive action potentials. Arrows indicate EADs.

Figure 5. Pretreatment of guinea pig ventricular myocytes with ranolazine (10  $\mu\text{mol/L}$ ) prevented hydrogen peroxide ( $\text{H}_2\text{O}_2$ , 200  $\mu\text{mol/L}$ )-induced prolongation of action potential duration.  $\text{H}_2\text{O}_2$  was applied in the absence (closed circle) or presence (open circle) of ranolazine. The action potential duration at 50% of repolarization ( $\text{APD}_{50}$ ) was normalized as percentage of control (before application of  $\text{H}_2\text{O}_2$ ), and was plotted against  $\text{H}_2\text{O}_2$  exposure time. Each point represents data collected from 3-10 cells. \*,  $p < 0.01$  vs. ranolazine-treated group.

Figure 6. Ranolazine (Ran, 10  $\mu\text{mol/L}$ ) attenuates hydrogen peroxide ( $\text{H}_2\text{O}_2$ , 200  $\mu\text{mol/L}$ )-induced contractile dysfunction of guinea pig ventricular myocytes. Panel A: amplitudes of twitch shortening of a single myocyte. Records were obtained in the absence (a) and presence (b-d) of drugs as indicated.  $\text{H}_2\text{O}_2$  (b) increased the amplitude of twitch shortening and induced aftercontractions (additional contractions during relaxation). Ran (c) suppressed the aftercontractions, but had little effect on the twitch amplitude. During washout of Ran in the continued presence of  $\text{H}_2\text{O}_2$  (d), the aftercontractions resumed and eventually spontaneous contractions with a decreased twitch amplitude appeared. Panel B: summary of experiments similar to those shown in Panel A. Each bar represents data collected from five cells. \* and \*\*,  $p < 0.05$  vs. control and  $\text{H}_2\text{O}_2$  alone, respectively; NS, no significant difference vs.  $\text{H}_2\text{O}_2$  alone.

Figure 7. Ranolazine (10  $\mu\text{mol/L}$ ) slows  $\text{H}_2\text{O}_2$  (200  $\mu\text{mol/L}$ )-induced increases of  $[\text{Na}^+]_i$  and diastolic  $[\text{Ca}^{2+}]_i$  in rabbit ventricular myocytes. Panels A, B and C: effect of  $\text{H}_2\text{O}_2$  on  $[\text{Na}^+]_i$ . A:

JPET #101832

original traces of SBFI fluorescence in the absence and presence of ranolazine before (0 min) and after a 12-min exposure to H<sub>2</sub>O<sub>2</sub> (in gray). B: time-course of changes in [Na<sup>+</sup>]<sub>i</sub>. Mean values for calibrated signals are normalized to baseline. C: concentrations of Na<sup>+</sup> measured at the end of a 12-min exposure to H<sub>2</sub>O<sub>2</sub>. Panels D, E and F: effect of H<sub>2</sub>O<sub>2</sub> on [Ca<sup>2+</sup>]<sub>i</sub>. D: original traces of Ca<sup>2+</sup> transient in the absence and presence of ranolazine before (0 min) and after a 12-min exposure to H<sub>2</sub>O<sub>2</sub> (in gray). Please note that in the absence of ranolazine, at the end of 12-min H<sub>2</sub>O<sub>2</sub> treatment the Ca<sup>+</sup> transients had disappeared, consistent with an early hypercontracture. E: time-course of changes in diastolic [Ca<sup>2+</sup>]<sub>i</sub>. Mean values for diastolic [Ca<sup>2+</sup>]<sub>i</sub> are normalized to baseline. F: diastolic [Ca<sup>2+</sup>]<sub>i</sub> determined after a 12-min exposure to H<sub>2</sub>O<sub>2</sub>.

Figure 8. An action of H<sub>2</sub>O<sub>2</sub> to increase late I<sub>Na</sub> is a potential mechanism by which H<sub>2</sub>O<sub>2</sub> prolongs action potential duration (APD) and causes early afterdepolarizations (EADs) and increases of intracellular [Na<sup>+</sup>] and [Ca<sup>2+</sup>]. TTX and ranolazine inhibit H<sub>2</sub>O<sub>2</sub>-induced late I<sub>Na</sub> (dashed arrow). ROS, reactive oxygen species; TTX, tetrodotoxin; Ran, ranolazine; NCX, Na<sup>+</sup>-Ca<sup>2+</sup> exchanger.

Figure 1




Figure 2







Figure 3











Figure 4



Downloaded from ipet.aspetjournals.org at ASPET Journals on April 18, 2022

Figure 5






Figure 6


A a. Control



b. H<sub>2</sub>O<sub>2</sub>




c. H<sub>2</sub>O<sub>2</sub> + Ran



d. H<sub>2</sub>O<sub>2</sub> (wash Ran)



B





# Figure 7





Figure 8



Downloaded from ipet.aspetjournals.org at ASPET Journals on April 18, 2024